



Real-world comparison of live attenuated and inactivated influenza vaccine effectiveness in Italian children

Vera Rigamonti ^{a,b,c}, Anna Cantarutti ^{a,*}, Vittorio Torri ^d,
 Francesca Ieva ^{d,e}, Carlo Giaquinto ^b, Costanza Di Chiara ^{b,f,g,1},
 Daniele Donà ^{b,1}, on behalf of the CARICE study group, CARICE study group

^a Department of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, University of Milan-Bicocca, Milan, Italy

^b Department of Women's and Children's Health, University of Padova, Padova, Italy

^c Società Servizi Telematici - Pedianet, Padova, Italy

^d MOX - Modelling and Scientific Computing Lab, Department of Mathematics, Politecnico di Milano, Milano, Italy

^e HDS - Health Data Science Centre, Human Technopole, Milano, Italy

^f Division of Infectious Diseases, The Hospital for Sick Children, Toronto, ON, Canada

^g Center for Global Child Health, The Hospital for Sick Children, Toronto, ON, Canada

ARTICLE INFO

Keywords:

Influenza
 Influenza vaccine
 Vaccine effectiveness
 Real-world data
 Population-based study
 Children

ABSTRACT

Background: Live attenuated (LAIV) and inactivated (IIV) influenza vaccines provide comparable protection in children, but differences in the timing of protection during the influenza season remain poorly characterized in real-world settings.

Methods: Using data from a large Italian primary care database, we conducted a retrospective population-based comparative effectiveness study comparing quadrivalent LAIV (LAIV-4) and IIV among children aged 2–14 years vaccinated during the 2023–2024 and 2024–2025 influenza seasons. Clinically diagnosed influenza and influenza-like illness (ILI) episodes were identified from clinical records. Vaccine effectiveness was assessed using time-to-event analyses based on restricted mean survival time (RMST).

Results: Overall effectiveness against influenza/ILI was similar between LAIV-4 and IIV across both seasons. However, temporal patterns differed, with LAIV-4 showing a trend toward earlier protection and IIV greater effectiveness during the 2023–2024 seasonal-peak.

Conclusions: LAIV-4 and IIV showed comparable overall effectiveness, although temporal patterns of protection varied across influenza seasons.

1. Introduction

Influenza is one of the most common respiratory infections in children, with high transmissibility and substantial morbidity each year [1–3]. Vaccination remains the most effective preventive strategy [4], and both live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) are recommended for pediatric use in many countries, including Italy [5]. Available evidence

indicates that LAIV and IIV provide broadly comparable overall protection against influenza-related clinical outcomes in children, supporting their use as alternative options within routine immunization programs [6–9]. However, less is known about how protection unfolds over time within the influenza season, particularly in real-world settings. This aspect may be especially relevant for vaccines with distinct immunologic mechanisms. While IIV primarily induces systemic humoral immunity, LAIV also elicits mucosal and

Abbreviations: LAIV, live attenuated influenza vaccine; IIV, inactivated influenza vaccine; LAIV-4, quadrivalent LAIV; NPL, natural language processing; ADI, area deprivation index; TTE, target trial emulation; RMST, restricted mean survival time; ICD-9-CM, international classification of diseases, ninth revision, clinical modification.

* Corresponding author.

E-mail addresses: v.rigamonti@sosepe.com (V. Rigamonti), anna.cantarutti@unimib.it (A. Cantarutti), vittorio.torri@polimi.it (V. Torri), francesca.leva@polimi.it (F. Ieva), carlo.giaquinto@unipd.it (C. Giaquinto), costanza.dichiara@unipd.it (C. Di Chiara), daniele.dona@unipd.it (D. Donà).

¹ Contributed as co-senior authors

<https://doi.org/10.1016/j.jvacx.2026.100856>

Received 21 January 2026; Received in revised form 27 May 2026; Accepted 11 June 2026

Available online 14 June 2026

2590-1362/© 2026 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

cellular immune responses, which could influence the timing of protection under real-world conditions [10,11].

These questions are particularly relevant in the post-COVID-19 period, during which influenza epidemiology has changed substantially, including shift in epidemic peak timing and more frequent co-circulation with other respiratory viruses. In Italy, the 2023–2024 and 2024–2025 influenza seasons were characterized by differing virologic and epidemiologic patterns [12,13], providing a contemporary setting to examine vaccine performance under heterogeneous conditions.

Building on our previous population-based analysis comparing each vaccine with no vaccination [14], the present study applied design principles inspired by target trial emulation to compare quadrivalent LAIV (LAIV-4) and IIV in a real-world setting. Rather than assessing vaccine superiority, we aimed to examine whether vaccines with distinct immunologic profiles exhibit different temporal patterns of effectiveness across recent influenza seasons.

2. Methods

2.1. Study design and data source

We conducted a population-based observational study using data from the Pédianet primary care database (<http://www.pedianet.it>), a nationwide network of community-based pediatricians across Italy. Pédianet collects longitudinal, individual-level clinical data, including demographics, diagnoses, prescriptions, and vaccinations, and has been widely used for pharmacoepidemiologic and vaccine effectiveness research.

The study applied selected design principles inspired by target trial emulation by aligning key elements of the observational design with those of a hypothetical randomized comparison between LAIV-4 and IIV in children [15]. A detailed mapping of the target trial components and their observational analogues is provided in eMethods 1.

2.2. Study population

We included children aged 2–14 years who received influenza vaccination during the 2023–2024 and 2024–2025 influenza seasons. The age range was selected based on national recommendations, as LAIV-4 is approved for use in children aged ≥2 years in Italy, and because children are routinely followed by family pediatricians up to 14 years of age within the Italian healthcare system, ensuring homogeneous follow-up within the same primary care setting [5]. Children with chronic comorbidities were excluded.

To ensure complete capture of exposures and outcomes, we included only children who adhered to the recommended well-child visit schedule and were followed by pediatricians adhering to the national influenza vaccination program [14].

2.3. Exposure and follow-up

Exposure was defined as receipt of LAIV-4 or IIV, as recorded in the Pédianet vaccination registry. The vaccination date was used as time zero. Follow-up continued until the first occurrence of an influenza/ILI episode, loss to follow-up (disenrollment from the pediatrician), or the end of the influenza season (April 30), whichever occurred first.

To account for differences in the onset of vaccine-induced immunity, observations were excluded if follow-up ended before the expected effectiveness period, defined as ≥7 days after vaccination for LAIV-4 and ≥ 14 days for IIV, based on prior evidence [16,17].

2.4. Outcome definition

The primary outcome was the occurrence of clinically diagnosed influenza/ILI. Events were identified using a validated algorithm leveraging both structured diagnostic codes and unstructured clinical

notes through natural language processing (NLP) [14]. A detailed description of the outcome identification algorithm is provided in eMethods 2.

Influenza-related hospitalization was also evaluated; however, the number of events was very limited in both seasons (2023–2024: 4 [0.15%] in the LAIV group vs 6 [0.22%] in the IIV group; 2024–2025: 1 [0.03%] vs 2 [0.06%], respectively), precluding meaningful comparative analyses.

2.5. Matching and statistical analysis

Children vaccinated with LAIV-4 were matched 1:1 with children vaccinated with IIV using pre-specified matching criteria, including sex, age, geographic area of residence (North, Center, and South and Islands), area deprivation index (ADI), and vaccination date (±3 days, time zero). ADI was used as an area-level proxy of socioeconomic deprivation and categorized as low versus high deprivation [18,19].

Vaccine effectiveness was compared using restricted mean survival time (RMST), which does not rely on proportional hazards assumptions, to estimate differences in time to influenza/ILI between vaccine groups.

A sensitivity analysis was conducted by restricting the outcome to influenza/ILI episodes occurring during the seasonal influenza peak, when clinical diagnoses are more likely to represent true influenza infections. The peak period was defined as December–January for the 2023–2024 season and January–February for the 2024–2025 season, based on national surveillance data [12,13]. For this analysis, only matched pairs in which vaccination was administered before the seasonal peak began were included.

Additionally, we performed an exploratory subgroup analysis restricted to matched pairs in which neither child had experienced influenza/ILI before the seasonal peak, to evaluate vaccine effectiveness during peak circulation among children still at risk at the beginning of the peak period.

Ethics approval and consent to participate.

This study was conducted in accordance with the principles of the Declaration of Helsinki. Data were encrypted and anonymized before use in compliance with Italian law and the General Data Protection Regulation. Participation in the Pédianet database required voluntary informed consent from parents or legal guardians.

3. Results

The matched cohorts included 2745 and 3385 children per group in the 2023–2024 and 2024–2025 influenza seasons, respectively. In both seasons, the sex distribution was approximately 47% female and 53% male. Median age was 5 years (IQR: 3–8) in both seasons, and the largest age group was 2–5 years, representing 59% and 51% of participants in the two seasons, respectively. Geographic area of residence and ADI distributions were similar across seasons, with most children residing in the North (approximately 55%) and in high-deprivation areas (43%) (eTable 1).

In both seasons, the proportion of children with an influenza/ILI episode before the vaccination date did not differ significantly between

Table 1
Number and percentage of children diagnosed with influenza/ILI in the LAIV-4 and IIV groups stratified by influenza season. Matched cohorts.

	LAIV-4	IIV	P-value ^a
2023–2024	N = 2745	N = 2745	
Influenza/ILI previous time zero – N (%)	3 (0.11)	2 (0.07)	1.000
Influenza/ILI (outcome) – N (%)	82 (2.99)	74 (2.70)	0.516
2024–2025	N = 3385	N = 3385	
Influenza/ILI previous time zero – N (%)	2 (0.06)	6 (0.18)	0.289
Influenza/ILI (outcome) – N (%)	101 (2.98)	123 (3.63)	0.135

^a Chi-square or Fisher's exact test, as appropriate; ILI: Influenza-Like Illness; LAIV-4: Live Attenuated Influenza Vaccine; IIV: Inactivated Influenza Vaccine.


LAIV-4 and IIV groups (Table 1). Overall, areas under the survival curves were similar between groups ($p = 0.747$ for 2023–2024; $p = 0.249$ for 2024–2025), although a slight trend favoring the LAIV-4 group was observed within the first 60 days after vaccination date in the 2023–2024 season ($p = 0.037$; Fig. 1). Sensitivity analyses restricted to influenza/ILI episodes occurring during the influenza peak showed seasonal variations. Overall, areas under the curve differed significantly in the 2023–2024 influenza season in favor of the IIV group ($p = 0.034$), whereas no significant difference was observed in the 2024–2025 season ($p = 0.102$) (Fig. 2). The exploratory subgroup analysis led to the same conclusions as the sensitivity analysis (data not shown).

4. Discussion

In this real-world matched analysis, LAIV-4 and IIV demonstrated comparable overall effectiveness against influenza/ILI among Italian children across the influenza seasons considered. This finding is in line with our previous population-based analysis comparing each vaccine with no vaccination [6–10]. However, during the 2023–2024 influenza season, a trend toward greater protection in the LAIV-4 group was observed within the first 60 days following vaccination, whereas IIV appeared more effective during the seasonal peak.


These temporal differences may reflect the distinct immunological profiles induced by the two vaccines. LAIV-4 mimics natural infection and induces mucosal and cellular immune responses in addition to systemic humoral immunity, which may contribute to a faster onset of protection and broader early immune activation compared with IIV [10,11]. While this observation raises the hypothesis that LAIV-4 could offer advantages when vaccination is initiated after influenza circulation has already begun, our findings should be interpreted cautiously. The present study was not designed to evaluate vaccination strategies or inform changes in immunization policy, and further studies specifically addressing vaccination timing and clinical outcomes would be required before drawing implications for vaccination recommendations.

Differences between seasons may also be influenced by the broader respiratory viral landscape. The 2023–2024 influenza season was characterized by an earlier influenza peak occurring shortly after a SARS-CoV-2 wave, suggesting a more sequential pattern of viral circulation. In contrast, the 2024–2025 season showed greater overlap of influenza with other respiratory viruses [12,13]. Sequential exposure to respiratory viruses, including SARS-CoV-2, followed by influenza, may transiently modulate host immune responses and susceptibility to subsequent infections, potentially influencing observed vaccine effectiveness patterns. However, this interpretation remains speculative.



LAIV-4: Live Attenuated Influenza Vaccine; IIV: Inactivated Influenza Vaccine

Fig. 1. Survival curves, Restricted Mean Survival Times (RMSTs), and 95% Confidence Interval (95% CI) from vaccination date to the end of the influenza season (April 30) for the 2023–2024 and 2024–2025 influenza seasons. Matched cohorts.



LAIV-4: Live Attenuated Influenza Vaccine; IIV: Inactivated Influenza Vaccine

Fig. 2. Sensitivity analysis. Survival curves, Restricted Mean Survival Times (RMSTs), and 95% Confidence Interval (95% CI) from vaccination date to the end of the influenza season (April 30), restricted to influenza/ILI episodes occurring during the seasonal influenza peak (December–January for 2023–2024 and January–February for 2024–2025). Matched cohorts.

Although the Peditnet database captures clinically diagnosed respiratory infections, individual-level information on laboratory-confirmed SARS-CoV-2 infection preceding influenza was not available in a form that would allow a formal evaluation of infection-sequence effects.

The main limitation of this study is that influenza/ILI episodes were identified using clinical definitions rather than laboratory confirmation, reflecting routine pediatric primary care practice. Consequently, some degree of outcome misclassification is possible, particularly during periods of co-circulation of other respiratory viruses. Moreover, the temporal patterns observed across seasons were not fully consistent and should therefore be interpreted cautiously. However, sensitivity analyses restricted to the influenza peak yielded results broadly consistent with the primary analysis, supporting the robustness of the findings. In addition, despite the application of selected design principles inspired by target trial emulation and careful matching on vaccination timing and key covariates, the observational nature of the study inherently exposes the analysis to potential residual confounding and limits causal

interpretation of the findings. Finally, the study population was restricted to children aged 2–14 years, reflecting the organization of pediatric primary care in Italy and limiting the generalizability of findings to older adolescents. Strengths include the use of a large population-based primary care database and the availability of longitudinal real-world clinical data collected under routine care conditions.

5. Conclusion

Overall, these findings support comparable effectiveness of LAIV-4 and IIV in pediatric populations while highlighting the importance of considering temporal patterns of protection and seasonal epidemiologic context when interpreting real-world influenza vaccine effectiveness.

Future studies should further investigate the duration and timing of vaccine-induced protection across influenza seasons and explore optimal vaccination strategies in pediatric populations.

Availability of data and materials

The data used in this study cannot be made publicly available due to Italian data protection laws. The anonymized datasets generated and/or analyzed during the current study can be provided upon request from the corresponding author, upon written approval from the Internal Scientific Committee (info@pedianet.it)

CRediT authorship contribution statement

Vera Rigamonti: Writing – original draft, Methodology, Formal analysis, Data curation. **Anna Cantarutti:** Writing – review & editing, Writing – original draft, Supervision, Software, Resources, Methodology, Investigation, Funding acquisition, Conceptualization. **Vittorio Torri:** Writing – review & editing, Formal analysis, Data curation. **Francesca Ieva:** Writing – review & editing, Methodology. **Carlo Giacchino:** Writing – review & editing, Investigation. **Costanza Di Chiara:** Writing – review & editing, Writing – original draft, Supervision. **Daniele Donà:** Writing – review & editing, Writing – original draft, Supervision, Conceptualization. **CARICE study group:** **Livia Antilici De Martini Di Valle Aperta, Alberto Argentiero, Riccardo Boracchini, Giulia Brigadoi, Beatrice Rita Campana, Susanna Maria Roberta Esposito, Valentina Fainardi, Hajrie Seferi, Alberto Villani, Anna Chiara Vittucci:** Writing – review & editing.

Consent for publication

The Internal Scientific Committee of Società Servizi Telematici Srl, the legal owner of Pedianet granted ethical approval and database access.

Funding/support

This work is supported by grants from the Italian Ministry of Education, University and Research (P20224MZE4), PNRR 2022-NAZ-0524 — PRIN 2022 under the National Recovery and Resilience Plan (PNRR), Mission 4, Component 2, Investment 1.1 – Call 1409/22: Covid-19 and Acute Respiratory Infections: the Clinical and Epidemiological Changes in the Pediatric Population (the CARICE project); CUP: H53D23007460001.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Anna Cantarutti reports financial support was provided by Italian Ministry of Education, University and Research. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors gratefully acknowledge the head of Pedianet, Dr. Luigi Cantarutti, and the contributions of all the family pediatricians participating in Pedianet network: Fabiana Accardo, Arturo Alberti, Stefano Alboresi, Katya Alessio, Federica Alfani, Eva Alfieri, Sara Alfieri, Michela Alfiero Bordigato, Monica Aloe, Anna Aloisio, Angelo Alongi, Domenico Amabile, Flavia Amaro, Denise Amato, Elena Amodio, Biagio Amoroso, Rosaria Ancarola, Barbara Andreola, Maria Luisa Andretta, Giampaolo Anese, Roberta Angelini, Maria Grazia Apostolo, Bruno Arcangeli, Giovanna Argo, Valentina Assirelli, Giovanni Avarello, Lucia Azzoni, Marta Bacciarini, Franco Balliana, Maria Carolina Barbazza, Maria Barberi Frandanisa, Patrizia Barbieri, Davide Bardella, Roberto Barone, Alice Bedini, Donatella Bellavere, Gabriele Belluzzi, Eleonora Benetti, Alessandra Beni, Chiara Maria Beretta, Fabio Berti, Roberto

Bezzi, Filippo Biasci, Claudio Biondi, Giovanni Battista Biserni, Franca Boe, Ilaria Boiani, Stefano Bollettini, Francesco Bonaiuto, Emanuela Bonfigli, Anna Maria Bontempelli, Matteo Bonza, Gloria Borsari, Elisa Bortoli, Claudia Bortolin, Giuseppe Boscarelli, Lucia Boselli, Sara Bozzetto, Cecilia Bresci, Rosa Britta, Andrea Bruna, Ivana Brusattera, Guido Brusoni, Mariella Bruzzese, Roberto Budassi, Massimo Caccini, Ilaria Cadel, Mariaclaudia Caiulo, Laura Calì, Maria Grazia Cammarata, Sonia Camposilvan, Laura Cantalupi, Luigia Caprio, Simone Carbogno, Chiara Cardarelli, Giovanna Carli, Sylvia Carnazza, Rita Casalboni, Anna Casani, Massimo Castaldo, Stefano Castelli, Serenella Castronuovo, Monica Cavedagni, Maria Silvia Cavinato, Cristina Cecamore, Stefania Censini, Giuseppe Egidio Cera, Chiara Chillemi, Rosa Maria Chiuri, Simona Ciccarelli, Francesca Cichello, Giuseppe Cicione, Niccolò Cilian, Anna Giulia Cimatti, Anna Cingolani, Carla Ciscato, Mariangela Clerici Schoeller, Samuele Cocchiola, Eleonora Coclite, Margherita Codifava, Marta Cofini, Maurizio Coletta, Giuseppe Collociani, Enrico Coltraro, Fabrizio Comaita, Ugo Alfredo Conte, Valeria Conte, Matteo Corchia, Francesca Corrias, Roberta Corro', Rosaria Costagliola, Nicola Costanzo, Sandra Cozzani, Giulia Cremonini, Giancarlo Cuboni, Giorgia Curia, Valentino Curti, Salvatore Curto, Caterina D'Alia, Vito Francesco D'Amanti, Michela D'Antoni, Antonio D'Avino, Alessandro D'Uva, Chiara Dalla Casa, Rita De Angelis, Roberto De Clara, Lorenzo De Giovanni, Annamaria De Marchi, Luisa De Marco, Chiara De Mutiis, Emanuele De Nicolò, Nicoletta De Polo, Irene Degrassi, Gian Piero Del Bono, Gigliola Del Ponte, Chiara Delehay, Fabio Dell'Antonia, Giovanna Di Corcia, Tiziana Di Giampietro, Simona Di Loreto, Giuseppe Di Mauro, Francesco Di Mauro, Salvatore Di Palma, Anna Paola Di Renzo, Giuseppe Di Santo, Piero Di Saverio, Mattea Dieli, Marco Dolci, Mattia Doria, Stefano Drago, Dania El Mazloum, Giuseppe Elio, Maria Carmen Fadda, Clara Maria Faedi, Bernadette Faggioli, Pietro Falco, Elena Falcon, Mario Fama, Marco Faraci, Maria Immacolata Farina, Alessio Favali, Tania Favilli, Susanna Fedeli, Mariagrazia Federico, Michele Felice, Maurizio Ferraiuolo, Enrico Ferrara, Marta Ferrarese, Michele Ferretti, Mauro Gabriele Ferretti, Paolo Forcina, Patrizia Foti, Claudio Paolo Frattini, Luisa Freo, Ezio Frison, Fabrizio Fusco, Teresa Fusco, Alessandra Gabutti, Ambra Gagliardo, Giovanni Gallo, Roberto Gallo, Andrea Galvagno, Livia Garlisi, Stefano Gastaldo, Alberta Gentili, Pierfrancesco Gentilucci, Erica Giacomelli, Giuliana Giampaolo, Giuseppe Giancola, Francesco Gianfredi, Letizia Giarretta, Eugenia Giraldi, Silvia Girotto, Isabella Giuseppin, Laura Gnesi, Costantino Gobbi, Renza Granzon, Mauro Grelloni, Mirco Grugnetti, Silvia Gulden, Marwan Hamarneh, Martina Ielo, Giorgia Inchingolo, Giulia Innocenzi, Angela Cristina Intini, Antonina Isca, Urania Elisabetta Lagrasta, Maurizio Lanci, Massimo Landi, Maura Lazzari, Maria Rosaria Letta, Francesca Levi Della Vida, Giuseppe Lietti, Marianna Ligas, Cinzia Lista, Giuseppe Lorusso, Riccardo Lucantonio, Elide Lucchi, Francesco Luise, Diego Luotti, Nadia Macropodio, Ivan Maddaluno, Matilde Maione, Tommaso Malusa, Elisabetta Manzali, Enrico Marano, Valeria Marchetti, Benedetta Marchi, Isabella Margherita, Francesca Marine, Lorenzo Mariniello, Pietro Marino, Gabriella Marostica, Valentina Marzetti, Sergio Masotti, Maura Mastrocola, Laura Mauri, Franco Mazzini, Clarissa Mazzotta, Rosa Maria Mele, Stefano Meneghetti, Annalisa Micheli, Francesca Micciotto, Massimo Milani, Stella Vittoria Milone, Antonella Minutoli, Donatella Moggia, Maria Chiara Molinari, Annalisa Monolo, Enrico Montagnani, Angela Maria Monteleone, Silvia Moretti, Giulia Maria Morresi, Angela Mortillaro, Annunziata Muggeri, Pierangela Mussinu, Carmen Muzzolini, Anna Naccari, Sara Nappini, Immacolata Naso, Novella Natale, Marina Navarra, Laura Nicoletti, Flavia Nicoloso, Erica Nistri, Monika Nitsch, Cristina Novarini, Laura Maria Olimpi, Riccardo Ongaro, Maria Maddalena Palma, Miriam Pambianchi, Angela Panariello, Vittorio Pandolfini, Stefano Pantano, Michael Panzenberger, Antonella Parlati, Enza Daniela Parrinello, Angela Pasinato, Andrea Passarella, Davide Pata, Viviana Dora Patianna, Pasquale Pazzola, Chiara Maria Pedrazzi, Monica Perin, Vanessa Perone, Cristina Perrera, Danilo Perri, Alberina Perrone, Sabrina Persia, Carla Alejandra Peruzzetto, Silvana Rosa Pescosolido, Giovanni Petrazzuoli, Giuseppe Petrotto, Vanna Piazza,

Patrizia Picco, Elvira Pinelli, Ambrogina Pirola, Lorena Pisanello, Daniele Pittarello, Eleonora Polidoro, Roberto Ponti, Elena Porro, Adolfo Francesco Porto, Alfonsina Postiglione, Alfiero Prandoni, Elisabetta Profumo, Chiara Protano, Antonino Puma, Maria Paola Puocci, Anna Lucia Quitadamo, Ruth Raffener, Ferdinando Ragazzon, Giulia Reghelin, Paolo Regini, Andrea Righetti, Riccardo Righini, Rosaria Rizzari, Maria Oliva Rizzi, Enrica Romano, Cristiano Rosafio, Paolo Rosas, Rino Rosignoli, Matilde Rossi, Mariella Rossitto, Bruno Ruffato, Lucia Ruggieri, Francesca Rusalen, Annamaria Ruscitti, Annarita Russo, Pietro Salamone, Cristina Salvatori, Daniela Sambugaro, Francesco Emilio Sanfilippo, Luigi Saretta, Vittoria Sarno, Marcella Sasso, Renato Savastano, Valentina Savio, Antonio Scarcella, Ghislaine Sciarone, Nico Maria Sciolla, Antonio Scorrano, Maria Sellitto, Flavio Semenzato, Rossella Semenzato, Paolo Senesi, Martina Serafini, Daniela Maria Sgroi, Romina Silenzi, Carla Silvan, Giorgia Soldà, Martina Soliani, Cristina Spagnoli, Valter Spanevello, Sergio Maria Speciale, Sabrina Spedale, Francesco Speranza, Sara Stefani, Francesco Storelli, Gianni Tamassia, Paolo Tambaro, Anna Taveggia, Albino Terenghi, Luisa Toderini, Marco Todeschini Premuda, Giacomo Toffol, Gabriele Tonelli, Ilaria Tosetto, Miro Trebbi, Silvia Tulone, Angelo Giuseppe Tummarello, Antonella Ulliana, Cristina Vallongo, Sergio Venditti, Claudia Ventrici, Leonello Venturelli, Giulia Vigo, Maria Grazia Vitale, Sergio Vivarelli, Francesco Paolo Volpe, Concetta Volpe, Barbara Vonella, Aldo Vozzi, Paola Wagner, Giulia Zanon, Chiara Zarbo, Maria Luisa Zuccolo.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jvaxc.2026.100856>.

Data availability

The authors do not have permission to share data.

References

- [1] Centers for Disease Control and Prevention. Estimated US Flu Disease Burden. Published on November 26. Available at, <https://www.cdc.gov/flu-burden/php/data-vis/index.html>. 2024.
- [2] Wang X, Li Y, O'Brien KL, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. *Lancet Glob Health* 2020;8:e497–510.
- [3] Smith KJ, Raviotta JM, DePasse JV, Brown ST, Shim E, Patricia Nowalk M, et al. Cost effectiveness of influenza vaccine choices in children aged 2–8 years in the U. S Am J Prev Med 2016;50(5):600–8. <https://doi.org/10.1016/j.amepre.2015.12.010>.
- [4] Cantarutti A, Barbieri E, Didon'e F, Scamarcia A, Giaquinto C, Corrao G.. Influenza vaccination effectiveness in paediatric 'healthy' patients: a population-based study in Italy. *Vaccines (Basel)* 2022;10(4):582. doi:10.3390/vaccines10040582.
- [5] Ministero della salute. Direzione generale della prevenzione sanitaria. Circolare 21 aprile 2023. In: Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2023–2024; 2023. Published on April 21. Accessed on March 20, 2024. Available at, https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=6229.
- [6] Caspard H, Gaglani M, Clipper L, et al. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the United States. *Vaccine* 2016;34(1):77–82. <https://doi.org/10.1016/j.vaccine.2015.11.010>.
- [7] Buchan SA, Booth S, Scott AN, et al. Effectiveness of live attenuated vs inactivated influenza vaccines in children during the 2012–2013 through 2015–2016 influenza seasons in Alberta, Canada: a Canadian immunization research network (CIRN) study. *JAMA Pediatr* 2018;172(9):e181514. <https://doi.org/10.1001/jamapediatrics.2018.1514>.
- [8] Boddington NL, Pearson I, Whitaker H, Mangtani P, Pebody RG. Effectiveness of influenza vaccination in preventing hospitalization due to influenza in children: a systematic review and meta-analysis. *Clin Infect Dis* 2021;73:1722–32.
- [9] Baum U, Kulathinal S, Auranen K, Nohynek H. Effectiveness of 2 influenza vaccines in nationwide cohorts of Finnish 2-year-old children in the seasons 2015–2016 through 2017–2018. *Clin Infect Dis* 2020;71:e255–61.
- [10] Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. *Hum Vaccin Immunother* 2018. <https://doi.org/10.1080/21645515.2017.1377376>. 14(3):571–8. Epub 2018 Jan 3. PMID: 28933664; PMCID: PMC5861782.
- [11] Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. *J Infect Dis* 2011;204:845–53.
- [12] <https://www.quotidianosanita.it/allegati/allegato/1746455558.pdf> [last accessed October 28th, 2025].
- [13] <https://www.epicentro.iss.it/ben/2024/4/respirimet-2023-2024> [last accessed October 28th, 2025].
- [14] Rigamonti V, Torri V, Morris SK, Ieva F, Giaquinto C, Donà D, et al. Cantarutti A. CARICE study group Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children *Vaccine* 2025 Apr 19;53: 126946. <https://doi.org/10.1016/j.vaccine.2025.126946>. Epub 2025 Feb 28. PMID: 40023131.
- [15] Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *Am J Epidemiol* 2016;183(8):758–64. <https://doi.org/10.1093/aje/kwv254>.
- [16] Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. *Pediatrics* 2007;120(3):e553–64. <https://doi.org/10.1542/peds.2006-2836>. Epub 2007 August 13. PMID: 17698577.
- [17] Zhu W, Higgs BW, Morehouse C, Streicher K, Ambrose CS, Woo J, et al. A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. *Vaccine* 2010;28(16):2865–76. <https://doi.org/10.1016/j.vaccine.2010.01.060>. Epub 2010 February 12. PMID: 20153794.
- [18] Vera R, Isabella R, Di Chiara C, Anna C, Cristina C. Sociodemographic and socioeconomic disparities in pediatric influenza vaccination: A cohort study from the pedianet network. *Vaccine* 2025;30(62):127494. <https://doi.org/10.1016/j.vaccine.2025.127494>.
- [19] Batzella E, Cantarutti A, Caranci N, Giaquinto C, Barbiellini Amidei C, Canova C. The association between Pediatric COVID-19 vaccination and socioeconomic position: nested case-control study from the Pedianet Veneto cohort. *JMIR Public Health Surveill* 2023;1(9):e44234. <https://doi.org/10.2196/44234>.